NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, ...
Hosted on MSN2mon
NRx stock rallies 35% on equity purchases, clinic acquisition
The firm will also be entitled to a seat on the boards of HOPE and NRx (NRXP). HOPE also announced it has signed a non-binding letter of intent to buy Florida-based Dura Medical, which operates ...
Nasdaq13d
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...
Hosted on MSN1y
NRx Pharmaceuticals Nears Completion of Pivotal Trial for Bipolar Depression Treatment
NRX-101, a patented combination of D-cycloserine ... Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA. It is the only oral medication that ...